Deals
Pfizer’s $3.6 Billion Deal for King Boosts Pain Focus
This article is for subscribers only.
Pfizer Inc.’s $3.6 billion purchase of King Pharmaceuticals Inc. adds abuse-resistant narcotics to help the drugmaker expand its share of the $22 billion market for painkillers.
Pfizer, the world’s largest drugmaker, will pay $14.25 a share in cash, a 40 percent premium over King’s closing price yesterday, for the morphine pill Embeda and two other tamper-resistant painkillers turned away once by U.S. regulators. The companies announced the deal today and expect it to close by the first quarter of 2011.